Detailed Narrative
Strong Q3 FY25 Financial Performance
Supriya Lifescience reported an impressive Q3 FY25, with revenue from operations growing 33% year-on-year to approximately INR 186 crores. This strong top-line growth translated into robust profitability, with EBITDA increasing by 59% to INR 66 crores, achieving a 35.5% margin. Profit After Tax (PAT) also saw significant growth, up 57% to INR 47 crores, with a PAT margin of 25%. For the first nine months of FY25, revenue reached INR 512 crores (up 24% YoY), EBITDA INR 193 crores (up 65% YoY), and PAT INR 137.5 crores (up 68% YoY).
Strategic Focus on Regulated Markets and Exports
The company's strategy to penetrate regulated markets is yielding results, with exports contributing 85% of total revenue in Q3 FY25, a notable increase from 74% in the same period last year. The LATAM region demonstrated remarkable growth, contributing 21% of the revenue this quarter compared to 8% last year, driven by approvals like 10 DMFs from CADIFA. The share of revenue from regulated markets increased to approximately 45% in Q3 FY25, up from less than 40% in Q3 FY24.
Capacity Expansion and Operational Efficiency
A significant milestone was achieved with the commissioning of the Module E block at the Lote Parshuram facility, adding 335 KLPD and bringing the total capacity to over 1,000 KLPD. This expansion, representing an investment of INR 125 crores, is expected to reach its peak revenue contribution by FY27. Operational efficiency also improved, with working capital days reducing to 124 days in Q3 FY25 from 134 days in the prior year.
New Product Pipeline and R&D Initiatives
Supriya Lifescience is continuously expanding its portfolio, with plans to launch at least 4 new products annually, and at least one new product launch expected every quarter. New therapeutic segments being targeted include anti-anxiety, anti-diabetics, and contrast media. The first contrast media product is expected to launch in Q2 FY26, with these products projected to be large contributors to revenue by FY27. The company's R&D facility in Ambernath is bolstering new formulations and CMO/CDMO business.
CMO/CDMO and Backward Integration Strategy
The company is capitalizing on the China+1 strategy, leveraging its strong regulatory and manufacturing background for CMO/CDMO opportunities. CMO is expected to contribute closer to 20% of total revenue by FY27. Backward integrated products currently contribute almost 77% of total revenue, a trend management intends to grow. The DSM project, a key CMO opportunity, will see its first commercial supply of 5-10 metric tons in Q4 FY25, with full potential of 25-30 metric tons by FY27.
Ambernath Facility and Whey Protein Project Update
The Ambernath facility is almost ready, with production expected to start in Q1 FY26, focusing initially on liquid inhalation products. Revenue generation from Ambernath is anticipated in Q4 FY25. Additionally, the company has secured the FSSAI license for its novel whey protein project, with revenue contribution expected to begin in FY26. The A21 land parcel will be utilized for scaling up whey protein volumes and warehousing activities.